Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
14 studies found for:    Kansas HCC sorafenib
Show Display Options
Rank Status Study
1 Recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Conditions: Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Drug: Sorafenib Tosylate;   Other: Placebo;   Drug: Doxorubicin Hydrochloride;   Drug: Doxorubicin-Eluting Beads;   Drug: Cisplatin;   Drug: Mitomycin;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
2 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Sorafenib Tosylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Active, not recruiting Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
4 Recruiting A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Drug: E7080;   Drug: Nexavar
5 Unknown  Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Condition: Liver Cancer
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate
6 Completed Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
7 Active, not recruiting
Has Results
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
8 Recruiting Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Sorafenib (BAY43-9006)
9 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib (XL184);   Drug: Placebo
10 Recruiting Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: Advanced Adult Hepatocellular Carcinoma
Intervention: Drug: Dalantercept plus sorafenib
11 Completed Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Suspended Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: INC280;   Drug: Placebo
13 Completed
Has Results
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Condition: Carcinoma
Interventions: Drug: Everolimus;   Drug: Everolimus Placebo;   Other: Best Supportive Care (BSC)
14 Active, not recruiting Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib;   Drug: Sorafenib

Indicates status has not been verified in more than two years